---
title: "Understanding the Market | GIANT BIOGENE rose over 5% in early trading as the Shaanxi Provincial Drug Administration reported that multiple batches of Kefu Mei products did not detect EGF"
description: "GIANT BIOGENE's stock rose over 5% in the morning session, and as of the time of writing, it is up 4.44%, trading at HKD 75.3, with a transaction volume of HKD 422 million. In terms of news, the domes"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/236885349.md"
published_at: "2025-04-22T03:33:06.000Z"
---

# Understanding the Market | GIANT BIOGENE rose over 5% in early trading as the Shaanxi Provincial Drug Administration reported that multiple batches of Kefu Mei products did not detect EGF

> GIANT BIOGENE's stock rose over 5% in the morning session, and as of the time of writing, it is up 4.44%, trading at HKD 75.3, with a transaction volume of HKD 422 million. In terms of news, the domestic beauty brand Kefu Mei has recently been embroiled in the "EGF additive scandal." The Shaanxi Provincial Drug Administration issued a statement regarding recent media reports about Kefu Mei's brand "detecting the prohibited additive epidermal growth factor (EGF)," stating that multiple batches of Kefu Mei products did not detect EGF. It is reported that Kefu Mei is the core brand of GIANT BIOGENE, with sales revenue reaching 4.542 billion yuan in 2024, a year-on-year increase of 62.9%, accounting for 82% of the company's total revenue. In addition, GIANT BIOGENE recently announced plans to conduct a rights issue at a discount of approximately 9.50%, aiming to raise a maximum net amount of about HKD 2.294 billion, which will be used for the development of core businesses and ecosystem layout, including brand promotion, marketing, category expansion, overseas business, and R&D investment; as well as to supplement working capital and for general corporate purposes. Citigroup released a research report stating that due to the significant discount, the stock price is expected to be under pressure in the short term. Nevertheless, GIANT BIOGENE's profit outlook remains robust

According to Zhitong Finance APP, GIANT BIOGENE (02367) rose over 5% in early trading, and as of the time of writing, it is up 4.44%, priced at HKD 75.3, with a transaction volume of HKD 422 million.

On the news front, the domestic beauty brand Kefu Mei has recently been embroiled in the "EGF addition scandal." The Shaanxi Provincial Drug Administration issued a notice regarding recent media reports that Kefu Mei products were found to contain the prohibited additive epidermal growth factor (EGF), stating that multiple batches of Kefu Mei products did not detect EGF. It is reported that Kefu Mei is the core brand of GIANT BIOGENE, with sales revenue reaching 4.542 billion yuan in 2024, a year-on-year increase of 62.9%, accounting for 82% of the company's total revenue.

In addition, GIANT BIOGENE recently announced plans to conduct a rights issue at a discount of approximately 9.50%, aiming to raise a maximum net amount of about HKD 2.294 billion, which will be used for the development of core business and ecosystem layout, including brand promotion, marketing, category expansion, overseas business, and R&D investment; as well as to supplement working capital and for general corporate purposes. Citigroup released a research report stating that due to the significant discount, the stock price is expected to be under pressure in the short term. Nevertheless, the earnings outlook for GIANT BIOGENE remains robust

### Related Stocks

- [02367.HK - GIANT BIOGENE](https://longbridge.com/en/quote/02367.HK.md)
- [C.US - Citigroup](https://longbridge.com/en/quote/C.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 早盤趨勢｜鉅子生物多頭信心鬆動，關鍵支撐岌岌可危？ | 1 月 27 日，鉅子生物（2367.HK）盤中弱勢震盪，盤面反覆探底，多次試探 28 元整數關口支撐未果。全天資金持續流出，綠盤成交佔比高，顯示多頭信心逐步鬆動，主力持倉籌碼開始鬆懈。 生物科技板塊過去一週受地方政策分歧影響，持續表現低迷 | [Link](https://longbridge.com/en/news/273815223.md) |
| 鉅子生物獲得中國批准推出全球首個膠原蛋白 - 透明質酸皮膚植入物 | 鉅子生物控股有限公司已獲得中國對其重組 I 型α1 亞型膠原蛋白和透明質酸複合溶液的批准，這是首個用於改善面頰光滑度的皮內注射產品。該產品增強了公司的膠原蛋白產品組合，並預計將為皮膚再生創造新的市場機會。目前，分析師對鉅子生物股票（HK:2 | [Link](https://longbridge.com/en/news/272675579.md) |
| 陶冬稱人民幣資產機會來了 科技自主牛市顯現 警示美債風險「黃金買貴不會買錯」 | 陶冬表示人民幣資產機會已來，科技自主牛市顯現，外資對中國資產前景看好。他指出當前應關注遠離央行控制的資產和科技突破。陶冬認為美聯儲將維持寬鬆政策，但短期內可能處於觀察期，且美債市場面臨風險，傳統的零風險資產邏輯已被顛覆。 | [Link](https://longbridge.com/en/news/276028904.md) |
| 美國與印尼敲定貿易協議 輸美商品關税降至 19% | 美國與印尼達成貿易協議，印尼輸美商品關税降至 19%。協議於去年 7 月宣佈，印尼在協議前面臨高達 32% 的關税威脅。協議內容包括豁免美國企業遵守自製率規定，並解決美國農產品在印尼的貿易障礙。此外，印尼同意採購價值 330 億美元的美國能 | [Link](https://longbridge.com/en/news/276423471.md) |
| 陶冬：人民幣資產機會來了 科技自主牛市顯現 警示美債風險「黃金買貴不會買錯」 | 陶冬表示，人民幣資產機會已來，科技自主牛市顯現，當前是「資產為王」的時代，關注遠離央行控制的資產和科技突破。預計美聯儲將維持寬鬆政策，但短期內可能觀察。美債市場面臨風險，傳統零風險資產邏輯已被顛覆，需警惕未來利率可能降至 3% 左右。 | [Link](https://longbridge.com/en/news/276028666.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.